Sachin Shukla1, Sharad K Mittal2, William Foulsham3, Elsayed Elbasiony2, Disha Singhania2, Srikant K Sahu4, Sunil K Chauhan5. 1. Schepens Eye Research Institute, Massachusetts Eye and Ear, Harvard Medical School, Boston, MA, USA; Center for Ocular Regeneration, L. V. Prasad Eye Institute, Hyderabad, India. 2. Schepens Eye Research Institute, Massachusetts Eye and Ear, Harvard Medical School, Boston, MA, USA. 3. Schepens Eye Research Institute, Massachusetts Eye and Ear, Harvard Medical School, Boston, MA, USA; Institute of Ophthalmology, University College London, London, UK. 4. Schepens Eye Research Institute, Massachusetts Eye and Ear, Harvard Medical School, Boston, MA, USA; L.V. Prasad Eye Institute, Bhubaneswar, Odisha, India. Electronic address: srikantsahu@lvpei.org. 5. Schepens Eye Research Institute, Massachusetts Eye and Ear, Harvard Medical School, Boston, MA, USA. Electronic address: sunil_chauhan@meei.harvard.edu.
Abstract
PURPOSE: Corneal injuries are associated with significant impairment in vision. Mesenchymal stem cells (MSCs) have been shown to limit inflammation and promote tissue repair at the ocular surface. Here, we evaluate the efficacies of different modes of MSC delivery (topical, subconjunctival, intraperitoneal [IP] and intravenous [IV]) to promote tissue repair and restore corneal transparency in a murine model of corneal injury. METHODS: MSCs were purified from the bone marrow of C57BL/6 mice and expanded using plastic adherence in vitro. Corneal injury was created using an Algerbrush, and 0.5 × 106 MSCs/mouse were administered via topical, subconjunctival, IP or IV routes. Qdot-labeled MSCs were employed to determine the effect of route of administration on corneal and conjunctival MSC frequencies. Corneal opacity scores were calculated using ImageJ. Expression of inflammatory cytokines was quantified by qPCR, and infiltration of CD45+ cells was evaluated by flow cytometry. RESULTS: Subconjunctival or IV administration results in increased frequencies of MSCs in ocular surface tissues following corneal injury, relative to topical or intraperitoneal delivery. Subconjunctival or IV administration reduces: (i) corneal opacity, (ii) tissue fibrosis as quantified by α-Sma expression, (iii) the expression of inflammatory cytokines (Il-1β and Tnf-α) and (iv) CD45+ inflammatory cell infiltration relative to untreated injured control animals. Administration via subconjunctival or IV routes was observed to accelerate corneal repair by restoring tissue architecture and epithelial integrity. CONCLUSIONS: Our data suggest that subconjunctival or IV delivery of MSCs has superior therapeutic efficacy compared to topical or IP delivery following corneal injury.
PURPOSE:Corneal injuries are associated with significant impairment in vision. Mesenchymal stem cells (MSCs) have been shown to limit inflammation and promote tissue repair at the ocular surface. Here, we evaluate the efficacies of different modes of MSC delivery (topical, subconjunctival, intraperitoneal [IP] and intravenous [IV]) to promote tissue repair and restore corneal transparency in a murine model of corneal injury. METHODS: MSCs were purified from the bone marrow of C57BL/6 mice and expanded using plastic adherence in vitro. Corneal injury was created using an Algerbrush, and 0.5 × 106 MSCs/mouse were administered via topical, subconjunctival, IP or IV routes. Qdot-labeled MSCs were employed to determine the effect of route of administration on corneal and conjunctival MSC frequencies. Corneal opacity scores were calculated using ImageJ. Expression of inflammatory cytokines was quantified by qPCR, and infiltration of CD45+ cells was evaluated by flow cytometry. RESULTS: Subconjunctival or IV administration results in increased frequencies of MSCs in ocular surface tissues following corneal injury, relative to topical or intraperitoneal delivery. Subconjunctival or IV administration reduces: (i) corneal opacity, (ii) tissue fibrosis as quantified by α-Sma expression, (iii) the expression of inflammatory cytokines (Il-1β and Tnf-α) and (iv) CD45+ inflammatory cell infiltration relative to untreated injured control animals. Administration via subconjunctival or IV routes was observed to accelerate corneal repair by restoring tissue architecture and epithelial integrity. CONCLUSIONS: Our data suggest that subconjunctival or IV delivery of MSCs has superior therapeutic efficacy compared to topical or IP delivery following corneal injury.
Authors: Masahiro Omoto; Kishore R Katikireddy; Alexandra Rezazadeh; Thomas H Dohlman; Sunil K Chauhan Journal: Invest Ophthalmol Vis Sci Date: 2014-09-16 Impact factor: 4.799
Authors: Sayan Basu; Andrew J Hertsenberg; Martha L Funderburgh; Michael K Burrow; Mary M Mann; Yiqin Du; Kira L Lathrop; Fatima N Syed-Picard; Sheila M Adams; David E Birk; James L Funderburgh Journal: Sci Transl Med Date: 2014-12-10 Impact factor: 17.956
Authors: Suneel Gupta; Michael K Fink; Duraisamy Kempuraj; Nishant R Sinha; Lynn M Martin; Landon M Keele; Prashant R Sinha; Elizabeth A Giuliano; Nathan P Hesemann; Sudhanshu P Raikwar; Shyam S Chaurasia; Rajiv R Mohan Journal: Mol Ther Date: 2022-07-02 Impact factor: 12.910
Authors: Lokendrakumar C Bengani; Hidenaga Kobashi; Amy E Ross; Hualei Zhai; Borja Salvador-Culla; Rekha Tulsan; Paraskevi E Kolovou; Sharad K Mittal; Sunil K Chauhan; Daniel S Kohane; Joseph B Ciolino Journal: Acta Biomater Date: 2020-08-16 Impact factor: 8.947
Authors: Sara Galindo; Ana de la Mata; Marina López-Paniagua; Jose M Herreras; Inmaculada Pérez; Margarita Calonge; Teresa Nieto-Miguel Journal: Stem Cell Res Ther Date: 2021-01-13 Impact factor: 6.832